BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 23300932)

  • 21. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
    Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
    Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling Anti-HIV-1 HSPC-Based Gene Therapy in Humanized Mice Previously Infected with HIV-1.
    Khamaikawin W; Shimizu S; Kamata M; Cortado R; Jung Y; Lam J; Wen J; Kim P; Xie Y; Kim S; Arokium H; Presson AP; Chen ISY; An DS
    Mol Ther Methods Clin Dev; 2018 Jun; 9():23-32. PubMed ID: 29322065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineering Cellular Resistance to HIV-1 Infection In Vivo Using a Dual Therapeutic Lentiviral Vector.
    Burke BP; Levin BR; Zhang J; Sahakyan A; Boyer J; Carroll MV; Colón JC; Keech N; Rezek V; Bristol G; Eggers E; Cortado R; Boyd MP; Impey H; Shimizu S; Lowe EL; Ringpis GE; Kim SG; Vatakis DN; Breton LR; Bartlett JS; Chen IS; Kitchen SG; An DS; Symonds GP
    Mol Ther Nucleic Acids; 2015 Apr; 4():e236. PubMed ID: 25872029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.
    Bai J; Banda N; Lee NS; Rossi J; Akkina R
    Mol Ther; 2002 Dec; 6(6):770-82. PubMed ID: 12498773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases.
    Li L; Krymskaya L; Wang J; Henley J; Rao A; Cao LF; Tran CA; Torres-Coronado M; Gardner A; Gonzalez N; Kim K; Liu PQ; Hofer U; Lopez E; Gregory PD; Liu Q; Holmes MC; Cannon PM; Zaia JA; DiGiusto DL
    Mol Ther; 2013 Jun; 21(6):1259-69. PubMed ID: 23587921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing.
    Knipping F; Newby GA; Eide CR; McElroy AN; Nielsen SC; Smith K; Fang Y; Cornu TI; Costa C; Gutierrez-Guerrero A; Bingea SP; Feser CJ; Steinbeck B; Hippen KL; Blazar BR; McCaffrey A; Mussolino C; Verhoeyen E; Tolar J; Liu DR; Osborn MJ
    Mol Ther; 2022 Jan; 30(1):130-144. PubMed ID: 34737067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CCR5 as a natural and modulated target for inhibition of HIV.
    Burke BP; Boyd MP; Impey H; Breton LR; Bartlett JS; Symonds GP; Hütter G
    Viruses; 2013 Dec; 6(1):54-68. PubMed ID: 24381033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model.
    ter Brake O; Legrand N; von Eije KJ; Centlivre M; Spits H; Weijer K; Blom B; Berkhout B
    Gene Ther; 2009 Jan; 16(1):148-53. PubMed ID: 18668146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivo.
    Sato K; Misawa N; Iwami S; Satou Y; Matsuoka M; Ishizaka Y; Ito M; Aihara K; An DS; Koyanagi Y
    PLoS Pathog; 2013; 9(12):e1003812. PubMed ID: 24339781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection.
    Zaitseva MB; Lee S; Rabin RL; Tiffany HL; Farber JM; Peden KW; Murphy PM; Golding H
    J Immunol; 1998 Sep; 161(6):3103-13. PubMed ID: 9743377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.
    Qin XF; An DS; Chen IS; Baltimore D
    Proc Natl Acad Sci U S A; 2003 Jan; 100(1):183-8. PubMed ID: 12518064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-gamma c-/- mice.
    Baenziger S; Tussiwand R; Schlaepfer E; Mazzucchelli L; Heikenwalder M; Kurrer MO; Behnke S; Frey J; Oxenius A; Joller H; Aguzzi A; Manz MG; Speck RF
    Proc Natl Acad Sci U S A; 2006 Oct; 103(43):15951-6. PubMed ID: 17038503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
    Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
    Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.
    Wolstein O; Boyd M; Millington M; Impey H; Boyer J; Howe A; Delebecque F; Cornetta K; Rothe M; Baum C; Nicolson T; Koldej R; Zhang J; Keech N; Camba Colón J; Breton L; Bartlett J; An DS; Chen IS; Burke B; Symonds GP
    Mol Ther Methods Clin Dev; 2014; 1():11. PubMed ID: 26015947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
    Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
    Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/differentiation of human target cells at the time of primary infection.
    Fais S; Lapenta C; Santini SM; Spada M; Parlato S; Logozzi M; Rizza P; Belardelli F
    J Virol; 1999 Aug; 73(8):6453-9. PubMed ID: 10400739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains.
    Huang L; Bosch I; Hofmann W; Sodroski J; Pardee AB
    J Virol; 1998 Nov; 72(11):8952-60. PubMed ID: 9765440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection.
    Anderson J; Akkina R
    Gene Ther; 2007 Sep; 14(17):1287-97. PubMed ID: 17597795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice.
    Hofer U; Henley JE; Exline CM; Mulhern O; Lopez E; Cannon PM
    J Infect Dis; 2013 Nov; 208 Suppl 2(Suppl 2):S160-4. PubMed ID: 24151324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV-1 infection and CD4 T cell depletion in the humanized Rag2-/-gamma c-/- (RAG-hu) mouse model.
    Berges BK; Wheat WH; Palmer BE; Connick E; Akkina R
    Retrovirology; 2006 Nov; 3():76. PubMed ID: 17078891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.